This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Izumino, K. Articles by Nagataki, S. Search for Related Content PubMed PubMed Citation Articles by Izumino, K. Articles by Nagataki, S.

Troglitazone Ameliorates Insulin Resistance in Patients with Werner’s Syndrome

First Department of Internal Medicine, Nagasaki University School of Medicine (K.I., H.S., M.I., H.T., H.Y., Y.Y., N.C., K.M., S.A., S.N.), Nagasaki; and the Laboratory of Biochemistry of Exercise and Nutrition, Institute of Health and Sports Sciences, University of Tsukuba (K.T.), Tsukuba, Ibaraki, Japan

Address all correspondence and requests for reprints to: Shigenobu Nagataki, M.D., First Department of Internal Medicine, Nagasaki University School of Medicine, 1–7-1 Sakamoto, Nagasaki 852, Japan.

Insulin resistance in Werner’s syndrome (WS) is probably due to defective signaling distal to the insulin receptor. To analyze the metabolic effects of troglitazone (TRO) in these patients, we performed frequently sampled iv glucose tolerance tests. Glucose kinetics were analyzed by the minimal model. Five patients with WS (mean age, 41.2 yr; body mass index, 17.0 kg/m²) were treated with TRO (400 mg/day) for 4 weeks. Each subject underwent a 75-g OGTT and frequently sampled iv glucose tolerance tests. Treatment reduced the area under the curve of glucose and insulin in the OGTT by 26% and 43%, respectively. Glucose tolerance, as manifested by the glucose disappearance rate improved significantly (1.36 ± 0.16 to 1.94 ± 0.30%/min; P < 0.05). Although the first phase insulin secretion was unchanged, insulin sensitivity and glucose effectiveness increased significantly [0.47 ± 0.11 to 1.38 ± 0.37 x 10^-4 min/pmol·L (P < 0.05) and 1.72 ± 0.17 to 2.52 ± 0.24 x 10^-2 min^-1 (P < 0.05), respectively]. However, treatment did not change glucose effectiveness at zero insulin. In patients with WS, TRO ameliorates glucose intolerance mediated by increased insulin sensitivity as well as glucose effectiveness, as assessed by minimal model analysis. TRO may modulate the postreceptor signaling component and be a clinically useful regimen for the treatment of patients with the intracellular insulin signaling defect.

This article has been cited by other articles:

				A. A. Parulkar, M. L. Pendergrass, R. Granda-Ayala, T. R. Lee, and V. A. Fonseca Nonhypoglycemic Effects of Thiazolidinediones Ann Intern Med, January 2, 2001; 134(1): 61 - 71. [Abstract] [Full Text] [PDF]

				L. S. Liu, H. Tanaka, S. Ishii, and J. Eckel The New Antidiabetic Drug MCC-555 Acutely Sensitizes Insulin Signaling in Isolated Cardiomyocytes Endocrinology, November 1, 1998; 139(11): 4531 - 4539. [Abstract] [Full Text] [PDF]

				N. A. Tritos and C. S. Mantzoros Syndromes of Severe Insulin Resistance J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3025 - 3030. [Full Text]

				J. Minamikawa, M. Yamauchi, D. Inoue, and H. Koshiyama Another Potential Use of Troglitazone in Noninsulin-Dependent Diabetes Mellitus J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 1041 - 1041. [Full Text]

				H. Yamasaki, K. Izumino, H. Takino, S. Nagataki, and Y. Yamaguchi Troglitazone Ameliorates Insulin Resistance in Patients with Werner's Syndrome--Author's Response J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 1041a - 1042. [Full Text]